BioSpace News Archive

Drug Development

ImmunoGen Plunges After Phase III Ovarian Cancer Treatment Fails to Hit PFS Endpoint

ImmunoGen’s FORWARD I trial was testing the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer.

March 1, 2019
·
2 min read
·
Alex Keown
Business

Abpro and China’s NJCTTQ Ink $4 Billion Development Deal

Abpro, based in Woburn, Mass., inked a deal worth up to $4 billion with China-based Nanjing Chia Tai Tianqing Pharmaceutical Company, known as NJCTTQ, a global pharmaceutical company.

March 1, 2019
·
3 min read
·
Mark Terry
Business

New Tools to the 4 Pillars of Cancer Treatment: Biomarker Testing and Chronic Cancers

Until recently, they were considered to be the three pillars of cancer treatment. Recent years have added a fourth pillar to surgery, radiation and chemotherapy—immuno-oncology.

March 1, 2019
·
5 min read
·
Mark Terry
Drug Development

Rani Therapeutics’ Biologics Smart-Pill Passes First-in-Human Trial

Most people would prefer to take a pill over an injection, and even an injection over an infusion. But not all drugs can be taken orally. In particular, this applies to most biologics, including insulin.

March 1, 2019
·
3 min read
·
Mark Terry
Drug Development

Researchers Identify New Genes That Could Play Key Role in Development of Alzheimer’s

An analysis of the genetics of nearly 95,000 people across the United States and Europe who have been diagnosed with Alzheimer’s disease has led to the discovery of four new genetic variants in the body that can increase the risk of developing the form of dementia.

March 1, 2019
·
3 min read
·
Alex Keown